Case Type: Mergers & Acquisitions

Knoll, Inc. (KNL) relating to its proposed acquisition by Herman Miller, Inc. Under the terms of the agreement, KNL shareholders are expected to receive $11.00 in cash and 0.32 shares of Herman Miller per share they own.

Colony Bancorp, Inc. (CBAN) relating to its proposed acquisition by SouthCrest Financial Group. Under the terms of the agreement, Southcrest shareholders are expected to receive either $10.45 in cash per share, or 0.7318 shares of CBAN per share they own.

BCTG Acquisition Corp. (BCTG) relating to its proposed merger with Tango Therapeutics, Inc. Under the terms of the agreement, will acquire Tango through a reverse merger, with Tango emerging as a publicly traded company.

Leaf Group, Ltd (LEAF) relating to its proposed acquisition by Graham Holdings Company. Under the terms of the agreement, LEAF shareholders are expected to receive $8.50 in cash per share.

SmartFinancial, Inc. (SMBK) relating to its proposed acquisition of Sevier County Banchares, Inc. Under the terms of the agreement, Sevier shareholders are expected to receive 0.90 shares of SMBK per share.

WSFS Financial Corp. (WSFS) relating to its proposed acquisition of Bryn Mawr Bank Corp. Under the terms of the agreement, Bryn Mawr shareholders are expected to receive 0.90 shares of WSFS per share.

D8 Holdings Corp. (DEH) relating to its proposed merger with Vicarious Surgical, Inc. Under the terms of the agreement, DEH will acquire Vicarious through a reverse merger, with Vicarious emerging as a publicly traded company.

Mudrick Capital Acquisition Corp. II (MUDS) relating to its proposed merger with Topps Co. Under the terms of the agreement, MUDS will acquire Topps through a reverse merger, with Topps emerging as a publicly traded company.

Rotor Acquisition Corp. (ROT) relating to its proposed merger with Sarcos Robotics. Under the terms of the agreement, ROT will acquire Sarcos through a reverse merger, with Sarcos emerging as a publicly traded company.

CA Healthcare Acquisition Corp. (CAHC) relating to its proposed merger with LumiraDx. Under the terms of the agreement, CAHC will acquire LumiraDx through a reverse merger, with LumiraDx emerging as a publicly traded company.